Postdoctoral researcher in the Department of Law at the University of Bergamo, Italy.
Postdoctoral researcher at the Department of Medical and Surgical Sciences at the University of Bologna, Italy, and a member of the Centre of Research in Clinical Ethics.
Ethics Hum Res. 2024 Sep-Oct;46(5):26-36. doi: 10.1002/eahr.500223.
At the height of the Covid pandemic, there was much discussion in the literature about using human challenge trials (HCTs) to expedite the development of effective Covid-19 vaccines. Historically, reluctance to fully accept HCTs has largely been due to potential conflicts with the principle of nonmaleficence in bioethics. Only a few commentators have explored this topic in depth. In this paper, we claim that to address ethical concerns regarding HCTs, two types of ethical reasons should be identified and investigated: first-order reasons that can be given to claim that a practice in itself is in direct conflict with the principles of bioethics; and second-order reasons that take into consideration how a practice is carried out and its consequences. We argue that understanding these ethical reasons is crucial for guiding the implementation of HCTs. We investigate a first-order reason against HCTs when the practice is in conflict with the principle of nonmaleficence, and when it is not. Following this argument and assuming there is no first-order reason based on nonmaleficence that hinders using HCTs, we argue there may be second-order reasons to guide implementation of this practice, such as difficulty in obtaining informed consent; protection of the weaker party; and trust in the scientific enterprise.
在新冠疫情高峰期,文献中广泛讨论了使用人体挑战试验(HCT)来加速有效的新冠疫苗的研发。从历史上看,人们对 HCT 的接受程度不高,主要是因为其与生物伦理学中的不伤害原则存在潜在冲突。只有少数评论员深入探讨了这一话题。在本文中,我们主张为了解决 HCT 相关的伦理问题,应确定并研究两类伦理理由:一类是可以直接宣称某一实践与生物伦理学原则相冲突的一阶理由;另一类是考虑实践的执行方式及其后果的二阶理由。我们认为,理解这些伦理理由对于指导 HCT 的实施至关重要。我们调查了当实践与不伤害原则冲突时反对 HCT 的一阶理由,以及当实践不与不伤害原则冲突时的情况。根据这一论点,并假设没有基于不伤害原则的一阶理由阻碍 HCT 的使用,我们认为可能存在二阶理由来指导这一实践的实施,例如知情同意的获取困难、保护弱势方以及对科学事业的信任。